Alto Ingredients Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 3/6
Alto Ingredients şirketinin kazançları yıllık ortalama -29.6% oranında azalırken, Chemicals sektörünün kazançları yıllık 3.8% oranında azalan oldu. Gelirler yıllık ortalama 3.7% oranında azalan oldu. Alto Ingredients şirketinin öz sermaye getirisi 11.7% olup, net marjı 3.1% dir.
Anahtar bilgiler
-29.59%
Kazanç büyüme oranı
-29.85%
EPS büyüme oranı
| Chemicals Sektör Büyümesi | 12.93% |
| Gelir büyüme oranı | -3.75% |
| Özkaynak getirisi | 11.72% |
| Net Marj | 3.06% |
| Son Kazanç Güncellemesi | 31 Mar 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Seeking Alpha • Jun 25
Alto Ingredients: A Profitable Turnaround In Progress With Upside Potential
Summary Alto Ingredients is executing a successful turnaround, shifting to a leaner, more resilient business model with improved profitability and operational focus. Q1 2026 results highlighted strong profitability, robust crush margins, and material contributions from Section 45Z tax credits, supporting sustainable earnings momentum. ALTO’s valuation, growth, and momentum metrics significantly outperform sector medians, with 482% 1-year price performance and EBITDA growth of 696% YoY. I rate ALTO a buy, citing operational catalysts, reliable tax credit income, and ample liquidity to fund capital projects despite commodity and regulatory risks. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 18
Alto Ingredients (ALTO) Stock Could Be 44.3% Undervalued After $8.9 Million 45Z Credit Sale
Alto Ingredients (ALTO) has drawn fresh attention after monetizing its 2025 Section 45Z Clean Fuel Production Tax Credits, securing about $8.9 million in cash that ties directly to its low-carbon ethanol operations. See our latest analysis for Alto Ingredients. That cash injection from Section 45Z tax credits lands at a time when Alto Ingredients’ share price has risen 88.53% year to date, with a 30 day share price return of 6.25% and a one year total shareholder return of 332.33%. These...
Anlatı Güncellemesi • Jun 18
ALTO: Stock Outlook Will Center On Future Clean Fuel Tax Credits
The analyst price target for Alto Ingredients has been revised from about $5.50 to roughly $10.00. Analysts attribute this change to updated assumptions on discount rates, profitability, and future P/E expectations.
Anlatı Güncellemesi • Jun 04
ALTO: Funded MASH Path And Liver Programs Are Expected To Drive Upside
Analysts have lifted the fair value estimate for Alto Ingredients to $9.00 from $6.75, reflecting updated assumptions around revenue growth, margins, and a lower projected P/E multiple informed by recent Street research on comparable clinical and funding setups. Analyst Commentary Recent Street research on peer companies in adjacent clinical and funding situations highlights how valuation work is being reshaped by dilution, funding visibility, and evolving program focus.
Anlatı Güncellemesi • May 15
ALTO: Future Returns Will Hinge On MASH Trials And Alcohol Liver Data
Alto Ingredients' analyst price target has been revised higher to $8.00 from $4.50, with analysts citing updated assumptions about the discount rate, revenue growth, profit margin, and future P/E to reflect recent research on the company's pipeline and market opportunities. Analyst Commentary While the revised US$8.00 price target reflects updated assumptions about Alto Ingredients' potential, some of the broader Street research on comparable stocks highlights why not all analysts are leaning in aggressively on valuation.Anlatı Güncellemesi • Apr 23
ALTO: MASH And Alcohol-Related Liver Programs Will Drive Future Upside Potential
Alto Ingredients' analyst fair value estimate has shifted from $4.00 to $6.75 as analysts factor in updated assumptions on discount rate, revenue growth, margins, and a higher future P/E in light of recent bullish coverage and revised price targets tied to pemvidutide's MASH and alcohol-related disease programs. Analyst Commentary Bullish Takeaways Bullish analysts are focused on pemvidutide as a differentiated asset for MASH and alcohol-related liver disease.Anlatı Güncellemesi • Apr 09
ALTO: Future Returns Will Depend On MASH Trials And Alcohol Liver Data
Analysts have raised Alto Ingredients' price target to $25 from $12, citing pemvidutide's potential in MASH and alcohol-related liver and use disorders as key factors behind the revision. Analyst Commentary Recent Street research on Alto Ingredients highlights a mixed backdrop, with optimistic views on pemvidutide and the MASH program set against more cautious assessments of risk and valuation.Anlatı Güncellemesi • Mar 26
ALTO: Future Returns Will Hinge On MASH Trials And Funding Discipline
Analysts have raised their average price target for Alto Ingredients to $25 from $12, citing a sharpened focus on the planned MASH pivotal program and added potential value from pemvidutide in alcohol use disorder and alcohol liver disease, along with a solid cash runway and upcoming clinical catalysts. Analyst Commentary Recent Street research on Altimmune reflects a mix of optimism around the clinical pipeline and caution around execution risks and valuation.Anlatı Güncellemesi • Mar 11
ALTO: Future Returns Will Depend On Execution And Funding Discipline
Analysts have raised their price target on Alto Ingredients to $4.50 from $3.00, citing updated assumptions around fair value, discount rate, expected revenue growth, profit margins, and future P/E that they say are more in line with recent Street research on comparable companies. Analyst Commentary While the higher price target reflects updated valuation work, some bearish analysts in the broader small cap space are still emphasizing execution and funding risks that can weigh on sentiment for companies like Alto Ingredients.Anlatı Güncellemesi • Feb 25
ALTO: Future Upside Will Depend On Delivering Consistent Margin Execution
Analysts have adjusted their price target on Alto Ingredients to $3.00, with the neutral fair value and updated assumptions on discount rate, revenue growth, profit margin, and future P/E reflecting a refined view of the company’s risk and earnings profile following recent supportive research coverage. Analyst Commentary Recent research on Alto Ingredients has focused on reassessing the balance between potential upside and the risks tied to execution, earnings quality, and market conditions.Anlatı Güncellemesi • Feb 11
ALTO: Fair Outlook Will Rely On Sustaining Margins And Execution
Analysts have raised their price target for Alto Ingredients to US$3.00, reflecting updated views that include modestly higher revenue growth, slightly stronger profit margins, a lower discount rate, and a revised future P/E assumption, supported in part by recent bullish Street research. Analyst Commentary While the updated US$3.00 price target points to a more constructive stance overall, some bearish analysts remain cautious and continue to flag risk around how Alto Ingredients can justify this valuation through execution and earnings delivery.Anlatı Güncellemesi • Jan 27
ALTO: Upcoming Liver Meeting Data Will Support Repriced Risk Reward Profile
Analysts recently trimmed their 12 month price target on Alto Ingredients by US$1 to US$14, citing refreshed assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts trimming price targets on comparable small cap names to around US$14, even when maintaining constructive ratings, suggest a tighter margin for error around assumptions such as discount rates, revenue growth, profit margins, and future P/E multiples.Anlatı Güncellemesi • Jan 12
ALTO: Upcoming Late-Stage Liver Data Will Support Repriced Risk Reward Profile
Narrative Update: Alto Ingredients Analyst Price Target Shift Analysts have trimmed their price target on Alto Ingredients by $1 to $14, citing updated risk and growth assumptions after the timing and outlook of recent clinical data were refined. Analyst Commentary Recent Street research reflects a more cautious tone, with bearish analysts trimming price targets and rechecking their assumptions on risk and potential upside.Anlatı Güncellemesi • Dec 26
ALTO: Upcoming Late-Stage Data Will Shape Risk Profile Amid Measured Outlook
Analysts have modestly lowered their price target on Alto Ingredients, trimming fair value by $1 to $14 as they factor in slightly softer long term assumptions, while remaining encouraged by upcoming late stage data presentations. Analyst Commentary Bearish analysts have pointed to the recent price target reduction to $14 as evidence that expectations for Alto Ingredients' long term growth and profitability are being tempered, even as upcoming late stage data remains a potential catalyst.Analiz Makalesi • Dec 22
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Shares Leap 41% Yet They're Still Not Telling The Full Story
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 41% gain in the last month...Anlatı Güncellemesi • Dec 12
ALTO: Lower Discount Rate Will Support Improved Risk Profile Ahead
Analysts have raised their price target on Alto Ingredients by about $0.50, citing a lower perceived risk profile driven by a reduced discount rate, stronger expected revenue growth, and a modest improvement in projected profit margins and future valuation multiples. Analyst Commentary Bearish analysts remain cautious on Alto Ingredients despite the recent upward revision to the price target, emphasizing that the new target still embeds a meaningful discount to peers on key growth and profitability metrics.Analiz Makalesi • Nov 07
Alto Ingredients, Inc. (NASDAQ:ALTO) Shares Fly 28% But Investors Aren't Buying For Growth
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 28% gain in the last month...Analiz Makalesi • Jul 04
Alto Ingredients, Inc. (NASDAQ:ALTO) Held Back By Insufficient Growth Even After Shares Climb 31%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 31% gain in the last month...
Yeni Anlatı • May 04
CO2 Plant Integration Will Boost Production And Exports
Acquisition and integration of the CO2 processing plant are expected to improve financials through cost synergies, increased capacity, and enhanced revenue streams.Analiz Makalesi • Apr 22
Health Check: How Prudently Does Alto Ingredients (NASDAQ:ALTO) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Nov 12
Alto Ingredients (NASDAQ:ALTO) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Jul 17
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Analiz Makalesi • Jun 28
Would Alto Ingredients (NASDAQ:ALTO) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Jan 15
Here's Why Alto Ingredients (NASDAQ:ALTO) Can Afford Some Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analiz Makalesi • Dec 20
Alto Ingredients, Inc. (NASDAQ:ALTO) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Those holding Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares would be relieved that the share price has rebounded 25% in...Analiz Makalesi • Sep 15
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Apr 10
We Think Alto Ingredients (NASDAQ:ALTO) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analiz Makalesi • Dec 16
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Alto Ingredients nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 26 | 916 | 28 | 27 | 0 |
| 31 Dec 25 | 918 | 12 | 27 | 0 |
| 30 Sep 25 | 922 | -51 | 28 | 0 |
| 30 Jun 25 | 933 | -68 | 24 | 0 |
| 31 Mar 25 | 951 | -60 | 30 | 0 |
| 31 Dec 24 | 965 | -60 | 30 | 0 |
| 30 Sep 24 | 1,003 | -37 | 28 | 0 |
| 30 Jun 24 | 1,069 | -39 | 32 | 0 |
| 31 Mar 24 | 1,150 | -28 | 29 | 0 |
| 31 Dec 23 | 1,223 | -29 | 30 | 0 |
| 30 Sep 23 | 1,278 | -43 | 34 | 0 |
| 30 Jun 23 | 1,297 | -68 | 32 | 0 |
| 31 Mar 23 | 1,341 | -53 | 32 | 0 |
| 31 Dec 22 | 1,336 | -43 | 28 | 0 |
| 30 Sep 22 | 1,393 | 26 | 31 | 0 |
| 30 Jun 22 | 1,361 | 51 | 30 | 0 |
| 31 Mar 22 | 1,297 | 37 | 30 | 0 |
| 31 Dec 21 | 1,208 | 44 | 29 | 0 |
| 30 Sep 21 | 991 | -12 | 27 | 0 |
| 30 Jun 21 | 890 | 7 | 27 | 0 |
| 31 Mar 21 | 804 | 13 | 29 | 0 |
| 31 Dec 20 | 897 | -16 | 32 | 0 |
| 30 Sep 20 | 1,086 | -37 | 37 | 0 |
| 30 Jun 20 | 1,246 | -80 | 39 | 0 |
| 31 Mar 20 | 1,380 | -102 | 37 | 0 |
| 31 Dec 19 | 1,425 | -90 | 35 | 0 |
| 30 Sep 19 | 1,402 | -81 | 33 | 0 |
| 30 Jun 19 | 1,407 | -61 | 33 | 0 |
| 31 Mar 19 | 1,471 | -67 | 35 | 0 |
| 31 Dec 18 | 1,515 | -62 | 36 | 0 |
| 30 Sep 18 | 1,576 | -43 | 36 | 0 |
| 30 Jun 18 | 1,651 | -36 | 36 | 0 |
| 31 Mar 18 | 1,646 | -31 | 35 | 0 |
| 31 Dec 17 | 1,632 | -36 | 35 | 0 |
| 30 Sep 17 | 1,679 | -10 | 38 | 0 |
| 30 Jun 17 | 1,651 | -13 | 35 | 0 |
| 31 Mar 17 | 1,669 | 1 | 33 | 0 |
| 31 Dec 16 | 1,625 | 0 | 32 | 0 |
| 30 Sep 16 | 1,560 | -14 | 26 | 0 |
| 30 Jun 16 | 1,523 | -25 | 28 | 0 |
| 31 Mar 16 | 1,327 | -29 | 25 | 0 |
| 31 Dec 15 | 1,191 | -20 | 25 | 0 |
| 30 Sep 15 | 1,071 | -7 | 20 | 0 |
Kaliteli Kazançlar: ALTO yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: ALTO geçmişte karlı hale geldi.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ALTO son 5 yılda karlı hale geldi ve kazançlarını yıllık -29.6% oranında artırdı.
Büyüme Hızlandırma: ALTO son bir yılda karlı hale geldi, bu da kazanç büyüme oranının 5 yıllık ortalamayla karşılaştırılmasını zorlaştırıyor.
Kazançlar vs. Sektör: ALTO son bir yılda karlı hale geldi ve bu durum, geçmiş yıl kazanç büyümesinin Chemicals sektörüyle ( -1.4% ) karşılaştırılmasını zorlaştırıyor.
Özkaynak Getirisi
Yüksek ROE: ALTO 'nin Özsermaye Getirisi ( 11.7% ) düşük olarak değerlendiriliyor.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/06 09:02 |
| Gün Sonu Hisse Fiyatı | 2026/07/02 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Alto Ingredients, Inc. 9 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Carter Driscoll | B. Riley Securities, Inc. |
| Hamed Khorsand | BWS Financial Inc. |
| Eric Stine | Craig-Hallum Capital Group LLC |